Creating new treatments for lymphoma using immune system activation
Development of pHLIP-phosphoantigen conjugates for lymphoma therapy
This study is testing a new treatment that helps your immune system better recognize and fight lymphoma, especially if other treatments haven't worked for you, by using a special drug that boosts certain immune cells to target cancer more effectively.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Connecticut Storrs NIH-funded |
| Lab location | 1 site (Storrs-Mansfield, United States) |
| Project ID | NIH-10818629 on NIH RePORTER |
What this research studies
This research focuses on enhancing the immune system's ability to identify and eliminate cancer cells, specifically targeting lymphoma types like diffuse large B cell lymphoma. The approach involves developing a drug conjugate that activates gamma delta T cells, which are crucial for a robust immune response against tumors. By targeting a specific protein, BTN3A1, the study aims to improve the effectiveness of immunotherapy for patients who have not responded well to existing treatments. This innovative method seeks to provide a new avenue for cancer treatment by leveraging the body's own immune mechanisms.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with diffuse large B cell lymphoma or other lymphomas that have shown resistance to current immunotherapy treatments.
Not a fit: Patients with lymphoma types that are not targeted by this research or those who have already responded well to existing immunotherapies may not benefit from this approach.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for patients with difficult-to-treat lymphomas.
How similar studies have performed: While the approach of targeting gamma delta T cells is promising, it is still relatively novel and has not been extensively tested in clinical settings for lymphoma treatment.
Where this research is happening
Storrs-Mansfield, United States
- University of Connecticut Storrs — Storrs-Mansfield, United States (Active)
Researchers
- Principal investigator: Wiemer, Andrew J — University of Connecticut Storrs
- Study coordinator: Wiemer, Andrew J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.